• 1
    Bronstein D.M., Perez-Otano I., Sun V., Mullis Sawin S.B., Chan J., Wu G.C., Hudson P.M., Kong L.Y., Hong J.S., McMillian M.K. (1995) Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 704 112116.
  • 2
    Chao C.C., Hu S., Peterson P.K. (1996) Glia: the not so innocent bystanders. J. Neurovirol. 2 234239.
  • 3
    Desagher S., Glowinski J., Premont J. (1996) Astrocytes protect neurons from hydrogen peroxide toxicity. J. Neurosci. 16 25532562.
  • 4
    Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J. Neurochem. 52 381389.
  • 5
    Dexter D.T., Jenner P., Schapira A.H., Marsden C.D. (1992) Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann. Neurol. 32 (Suppl.) , S94S100.
  • 6
    Dexter D.T., Sian J., Rose S., Hindmarsh J.G., Mann V.M., Cooper J.M., Wells F.R., Daniel S.E., Lees A.J., Schapira A.H. , et al. (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35 3844.
  • 7
    Di Porzio U., Daguet M.C., Glowinski J., Prochiantz A. (1980) Effect of striatal cells on in vitro maturation of mesencephalic dopaminergic neurones grown in serum-free conditions. Nature 288 370373.
  • 8
    Druckarch B., Schepens C.A.M., Jongenelen J.C., Stoof C.H., Langeveld C.H. (1997) Astrocyte-mediated enhancement of neuronal survival is abolished by glutathione deficiency. Brain Res. 770 123130.
  • 9
    Engele J. & Bohn M.C. (1991) The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia [published erratum appears in J. Neurosci. (1992) 12, 685]. J. Neurosci. 11 30703078.
  • 10
    Fahn S. & Cohen G. (1992) The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann. Neurol. 32 804812.
  • 11
    Farooqui A.A., Yang H., Rosenberger T.A., Horrocks L.A. (1997) Phospholipase A2 and its role in brain tissue. J. Neurochem. 69 889901.
  • 12
    Giulian D., Vaca K., Corpuz M. (1993) Brain glia release factors with opposing actions upon neuronal survival. J. Neurosci. 13 2937.
  • 13
    Han S., Mytilineou C., Cohen G. (1996) L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. 66 501510.
  • 14
    Heales S.J., Bolanos J.P., Clark J.B. (1996) Glutathione depletion is accompanied by increased neuronal nitric oxide synthase activity. Neurochem. Res. 21 3539.
  • 15
    Hou J., Cohen G., Mytilineou C. (1997) Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: involvement of the glutathione system. J. Neurochem. 69 7683.
  • 16
    Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E.C. (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72 355363.
  • 17
    Jenner P. & Olanow C.W. (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47 (Suppl.) , S161S170.
  • 18
    Jeohn G.H., Kong L.Y., Wilson B., Hudson P., Hong J.S. (1998) Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. J. Neuroimmunol. 85 110.
  • 19
    Kalir H.H. & Mytilineou C. (1991) Ascorbic acid in mesencephalic cultures: effects on dopaminergic neuron development. J. Neurochem. 57 458464.
  • 20
    Katsuki H. & Okuda S. (1995) Arachidonic acid as a neurotoxic and neurotrophic substance. Prog. Neurobiol. 46 607636.
  • 21
    Katsuki H., Akino N., Okuda S., Saito H. (1995) Antioxidants, but not cAMP or high K+, prevent arachidonic acid toxicity on neuronal cultures. Neuroreport 6 11011104.
  • 22
    Korystov Y.N., Dobrovinskaya O.R., Shaposhnikova V.V., Eidus L. (1996) Role of arachidonic acid metabolism in thymocyte apoptosis after irradiation. FEBS Lett. 388 238241.
  • 23
    Li Y., Maher P., Schubert D. (1997) A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19 453463.
  • 24
    Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 265275.
  • 25
    McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38 12851291.
  • 26
    Meister A. (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther. 51 155194.
  • 27
    Merad-Boudia M., Nicole A., Santiard-Baron D., Saille C., Ceballos-Picot I. (1998) Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson’s disease. Biochem. Pharmacol. 56 645655.
  • 28
    Michel P.P., Ruberg M., Agid Y. (1997) Rescue of mesencephalic dopamine neurons by anticancer drug cytosine arabinoside. J. Neurochem. 69 14991507.
  • 29
    Minghetti L. & Levi G. (1998) Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog. Neurobiol. 54 99125.
  • 30
    Mogi M., Harada M., Kondo T., Narabayashi H., Riederer P., Nagatsu T. (1995) Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson’s disease. Neurosci. Lett. 193 129132.
  • 31
    Moore S.A., Yoder E., Murphy S., Dutton G.R., Spector A.A. (1991) Astrocytes, not neurons, produce docosahexaenoic acid (22:6ω-3) and arachidonic acid (20:4ω-6). J. Neurochem. 56 518524.
  • 32
    Murphy T.H., Miyamoto M., Sastre A., Schnaar R.L., Coyle J.T. (1989) Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 2 15471558.
  • 33
    Mytilineou C., Han S., Cohen G. (1993) Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J. Neurochem. 61 14701478.
  • 34
    Mytilineou C., Leonardi E.K., Radcliffe P., Heinonen E.H., Han S., Werner P., Cohen G., Olanow C.W. (1998) Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J. Pharmacol. Exp. Ther. 284 700706.
  • 35
    Park T.H. & Mytilineou C. (1992) Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP+-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF. Brain Res. 599 8397.
  • 36
    Perry T.L., Godin D.V., Hansen S. (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33 305310.
  • 37
    Perry V.H. (1994) Modulation of microglia phenotype. Neuropathol. Appl. Neurobiol. 20 177.
  • 38
    Philbert M.A., Beiswanger C.M., Waters D.K., Reuhl K.R., Lowndes H.E. (1991) Cellular and regional distribution of reduced glutathione in the nervous system of the rat: histochemical localization by mercury orange and o-phthaldialdehyde-induced histofluorescence. Toxicol. Appl. Pharmacol. 107 215227.
  • 39
    Pileblad E., Eriksson P.S., Hansson E. (1991) The presence of glutathione in primary neuronal and astroglial cultures from rat cerebral cortex and brain stem. J. Neural Transm. Gen. Sect. 86 4349.
  • 40
    Piomelli D. (1993) Arachidonic acid in cell signaling. Curr. Opin. Cell Biol. 5 274280.
  • 41
    Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52 515520.
  • 42
    Sagara J.I., Miura K., Bannai S. (1993) Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61 16721676.
  • 43
    Scow R.O. & Blanchette-Mackie E.J. (1985) Why fatty acids flow in cell membranes. Prog. Lipid Res. 24 197241.
  • 44
    Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 36 348355.
  • 45
    Simmons M.L. & Murphy S. (1992) Induction of nitric oxide synthase in glial cells. J. Neurochem. 59 897905.
  • 46
    Slivka A., Mytilineou C., Cohen G. (1987) Histochemical evaluation of glutathione in brain. Brain Res. 409 275284.
  • 47
    Snyder S.H. & Bredt D.S. (1991) Nitric oxide as a neuronal messenger. Trends Pharmacol. Sci. 12 125128.
  • 48
    Sofic E., Lange K.W., Jellinger K., Riederer P. (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci. Lett. 142 128130.
  • 49
    Takeshima T., Shimoda K., Sauve Y., Commissiong J.W. (1994) Astrocyte-dependent and -independent phases of the development and survival of rat embryonic day 14 mesencephalic, dopaminergic neurons in culture. Neuroscience 60 809823.
  • 50
    Tang D.G., Chen Y.Q., Honn K.V. (1996) Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc. Natl. Acad. Sci. USA 93 52415246.
  • 51
    Tietze F. (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem. 27 502522.
  • 52
    Vernadakis A. (1988) Neuron-glia interrelations. Int. Rev. Neurobiol. 30 149224.